REGISTER

Register today to view and participate in our Webinar series.

Helpful Resources

This page provides helpful resources, including information about support and assistance, downloadable resources, links to advocacy organizations and more.

How to participate

Be sure to have your user name and password ready. You should have received this information via e-mail when you registered for the Somatuline^® Depot Acromegaly Answers Webinar Series.
If you did not already sign up, but would like to participate in the Webinar series, register now.
On the date and time of the Webinar, return to www.AcromegalyAnswersWebinar.com and click on the Webinars tab to log in approximately 15 minutes before the Webinar is scheduled to begin.
Archives will be available if you miss the date of the live webinar.
The following system requirements are needed in order to access the Somatuline^® Depot Acromegaly Answers Webinar Series online:

A computer (PC or Mac) with speakers
High-speed Internet connection (not dial-up)
Web browser (Mozilla Firefox is recommended)
Adobe Flash Player 8 or higher (download for free from Adobe.com)
For optimal viewing, set your screen resolution to 1024 x 768 or higher

Valuable Resources

To help you understand acromegaly and the importance of taking medical therapy, like Somatuline^® Depot (lanreotide) Injection as prescribed, download and print the patient resources pictured here.

Somatuline^® Depot Freedom Kit

This kit includes everything you need to find the acromegaly therapy that best suits your condition and lifestyle.

Acromegaly Therapy Companion Chart - compares various therapies for acromegaly
Somatuline^® Depot Injection and Proper Usage - explains directions for dosage and easy administration
What to Expect When You Switch Brochure – delivers in-depth information to help you make an informed decision
New Directions Patient Brochure - provides information about acromegaly and Somatuline^® Depot, a therapy to help you manage it
Fast Facts - answers questions about Somatuline^® Depot

Advocacy Organizations

Visit the Web sites of the organizations below for more information about acromegaly:

The Pituitary Network Association (PNA), an international non-profit organization for patients with acromegaly, their families, loved ones, and the physicians and healthcare providers who treat them: www.pituitary.org or www.acromegaly.org.

The Pituitary Tumor Center of Massachusetts General Hospital - provided by Harvard Medical School: http://pituitary.mgh.harvard.edu/.

National Organization for Rare Disorders (NORD) includes acromegaly in its rare-disease database and will e-mail or fax a full report for a nominal fee: http://www.rarediseases.org.

Somatuline^®Depot.com is a Web site devoted to providing information about acromegaly, its symptoms and diagnosis, and treatment with the advanced somatostatin analog, Somatuline^® Depot: http://www.SomatulineDepot.com/.

The Pituitary Society is dedicated to furthering the understanding of diseases of the pituitary gland, highlighting advances in clinical care, and honoring outstanding contributions to research: http://www.pituitarysociety.org.

Cedars-Sinai Pituitary Center is committed to providing the highest quality patient care. The quality of care is measured in high patient satisfaction scores, continuous clinical performance initiatives, excellent medical outcomes, and ongoing research: http://www.cedars-sinai.edu/9966.html.

Ohio State University Comprehensive Cancer Center / James Cancer Hospital and Solove Research Institute are an excellent healthcare enterprise focused on improving the lives of cancer patients. The center is dedicated to translating research into quality patient care: http://www.jamesline.com/about/Pages/index.aspx.

Important Indication and Safety Information

Somatuline^® Depot (lanreotide) Injection is a somatostatin analog indicated for the long-term treatment of patients with acromegaly who have had an inadequate response to or cannot be treated with surgery and/or radiotherapy.

Lanreotide may reduce gallbladder motility and lead to gallstone formation. Periodic monitoring may be needed. Patients treated with Somatuline^® Depot (lanreotide) Injection may experience hypoglycemia or hyperglycemia. Glucose levels monitoring is recommended and antidiabetic treatment adjusted accordingly. Lanreotide may lead to a decrease in heart rate. Use with caution in at-risk patients.

Patients with moderate and severe renal impairment or moderate and severe hepatic impairment should begin treatment with Somatuline^® Depot (lanreotide) Injection 60mg.

There are no adequate and well controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human responses, Somatuline^® Depot (lanreotide) Injection should be used during pregnancy only if the potential benefit justifies risk to the fetus. A decision should be made whether to discontinue nursing or discontinue the drug taking into account the importance of the drug to the mother.

Somatuline^® Depot may decrease the bioavailability of cyclosporine. Cyclosporine dose may need to be adjusted to maintain levels.

Patients receiving beta-blockers, calcium channel blockers, or other drugs that affect heart rate may need dose adjustments. Somatuline^® Depot (lanreotide) Injection may reduce the intestinal absorption of co-administered drugs. Caution should be used.

The most common adverse reactions (incidence >5%) are diarrhea, cholelithiasis, abdominal pain, nausea, injection site reaction, flatulence, arthralgia, and loose stools.

Please see Full Prescribing Information for additional important information.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.FDA.gov/medwatch or call 1-800-FDA-1088.